Home /
Biologic therapy – Dana-Farber Cancer Institute – Treatment Details
|
|
| Description: |
| Patients: This phase 2 study involved 24 patients with malignant plural mesothelioma. There were 15 men and 9 women, ranging in age from 38 to 76 years of age. The median age was 62.5 years old. These patients had been treated with chemotherapy before.
Treatment: Patients were treated with bevacizumab and erlotinib. These are biological therapies. Toxicity: Grade 4 pulmonary embolism was reported in one patient, and grade 3 deep vein thrombosis in another. The most common toxicities were rash and diarrhea. Grade 3 rash was reported in 17% of patients, and grade 3 diarrhea in 8% of patients. Grade 1 and 2 toxicities (milder) were more common, and included rash, diarrhea, anorexia, fatigue, dry skin, nausea, mouth sores, and dizziness. Results: The median overall survival was 5.8 months. The authors concluded that these therapies were not really effective in treating mesothelioma. Support: This study was supported in part by Genentech, Inc., which markets erlotinib as Tarceva and bevacizumab as Avastin. Correspondence: Dr. Pasi A. Janne |
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."